Life Sciences Innovative Manufacturing Fund

The Life Sciences Innovative Manufacturing Fund is a major UK government intervention administered through the Department for Science, Innovation and Technology, providing deep capital to attract globally mobile drug manufacturing and bioprocessing infrastructure investment to the UK. Headquartered in London, the program targets biotech, pharma/therapeutics, and life sciences tools projects where manufacturing scale and national health resilience are at stake. It is policy capital with industrial strategy goals, not traditional venture funding.

The fund deploys checks of $25M and above at Growth stage, typically structured as grants or co-investments tied to capital expenditure, facility builds, and job creation in the UK. Eligibility is restricted to projects with substantive UK manufacturing footprint commitments, and awards are competitive and milestone-gated.

Founders should treat this as a strategic non-dilutive or partially dilutive capital source layered onto a private equity or venture round, not a substitute for one. Expect formal application windows, detailed economic-impact modeling, and a long evaluation cycle. Engage early with industry trade bodies and government contacts, and align the ask with national priorities around resilience, jobs, and advanced manufacturing capability.